The use of selective aldosterone antagonists

Current Hypertension Reports

Volumn 6, Issue 5, 2004, Pages 342-345

  Weinberger, Myron H ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACEBO; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; GYNECOMASTIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; RECEPTOR BLOCKING; SYSTOLIC HYPERTENSION; THROMBOCYTE ACTIVATION;

EID: 5444227854     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0051-3     Document Type: Article

References (25)

1. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341: 709-717.
2. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective adosterone blocker in mild-to-moderate hypertension. Am J Hypertension 2002, 15: 709-716.
3. Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40: 117-123.
4. Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41: 1148-1155.
5. White WB, Duprez D, St-Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41: 1021-1026.
6. White W, Carr A, Krause S, et al.: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92: 38-42.
7. Burgess E, Lacouciere Y, Ruilope L, et al.: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2002, 25: 2388-2404.
8. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108: 1831-1838.
9. Williams GH, Burgess E, Kolloch RE, et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93: 990-996.
10. Epstein M, Weinberger MH, Lewin A, et al.: The selective aldosterone blocker, eplerenone, reduces proteinuria without concomitant hyperkalemia (abstract). J Am Soc Nephrol 2003, 14: 6A.
11. Epstein M, Buckalew V Jr, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria (abstract). Am J Hypertension 2002, 15: 24A.
12. Epstein M, Buckalew V, Altomirano J, et al.: Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. J Am Coll Cardiol 2002, 39: Suppl A.
13. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60: 820-825.
14. Hollenberg NK, Williams GH, Anderson R, et al.: Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003, 163: 1543-1548.
15. Verdecchia P, Porcellati C, Reboldi G, et al.: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001, 104: 2039-2066.
16. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115: 41-46.
17. Vasan RS, Evans JC, Benjamin EJ, et al.: Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004, 43: 957-962.
18. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-1321.
19. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67: 1355-1364.
20. Young MJ, Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996, 271: E883-E888.
21. Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinol 2000, 141: 3871-3878.
22. Blasi ER, Rocha R, Rudolph AE, et al.: Aldsoterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kid Int 2003, 63: 1791-1800.
23. Oberleithner H, Ludwig T, Riethmuller C, et al.: Human endothelium: target for aldosterone. Hypertension 2004, 43: 952-956.
24. Schafer A, Fraccarollo D, Hidemann SK, et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003, 58: 655-662.
25. Schafer A, Fraccarollo D, Hildemann S, et al.: Inhibition of platelet aggregation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003, 89: 1024-1030.